Correction: Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications (JACC: Heart Failure (2019) 7(6) (505–515), (S2213177919302318), (10.1016/j.jchf.2019.03.011));Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications

JACC: Heart Failure

Volumn 7, Issue 6, 2019, Pages 505-515

  Stolfo, Davide ^a,b   Uijl, Alicia ^a,c   Vedin, Ola ^d   Strömberg, Anna ^e   Faxén, Ulrika Ljung ^a,f   Rosano, Giuseppe M C ^g   Sinagra, Gianfranco ^b   Dahlström, Ulf ^e   Savarese, Gianluigi ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UPPSALA UNIVERSITY   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

gender; heart failure; heart failure with mid range ejection fraction; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; outcome; registry; sex

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; CARDIOTONIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGISTER; SEX DIFFERENCE; AGE DISTRIBUTION; CARDIAC RESYNCHRONIZATION THERAPY; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; SEX FACTOR; STATISTICAL MODEL; SWEDEN; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOTONIC AGENTS; DIABETES MELLITUS; DIGOXIN; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL ISCHEMIA; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STROKE VOLUME; SWEDEN;

EID: 85065788043     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2020.02.002     Document Type: Erratum

References (26)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
2. Braunwald, E., Heart failure. J Am Coll Cardiol HF 1 (2013), 1–20.
3. Hsich, E.M., Pina, I.L., Heart failure in women: a need for prospective data. J Am Coll Cardiol 54 (2009), 491–498.
4. Dewan, P., Rorth, R., Jhund, P.S., et al. Differential impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol 73 (2019), 29–40.
5. Jonsson, A., Edner, M., Alehagen, U., Dahlstrom, U., Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 12 (2010), 25–31.
6. Pina, I.L., Kokkinos, P., Kao, A., et al. Baseline differences in the HF-ACTION trial by sex. Am Heart J 158 (2009), S16–S23.
7. Redfield, M.M., Jacobsen, S.J., Borlaug, B.A., Rodeheffer, R.J., Kass, D.A., Age– and gender-related ventricular-vascular stiffening: a community-based study. Circulation 112 (2005), 2254–2262.
8. Lam, C.S., Lund, L.H., Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart 102 (2016), 257–259.
9. Zafrir, B., Lund, L.H., Laroche, C., et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14,964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J 39 (2018), 4277–4284.
10. Beale, A.L., Meyer, P., Marwick, T.H., Lam, C.S.P., Kaye, D.M., Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation 138 (2018), 198–205.
11. Walsh, M.N., Jessup, M., Lindenfeld, J., Women with heart failure: unheard, untreated, and unstudied. J Am Coll Cardiol 73 (2019), 41–43.
12. Chatterjee, N.A., Borgquist, R., Chang, Y., et al. Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Eur Heart J 38 (2017), 1485–1494.
13. Zusterzeel, R., Selzman, K.A., Sanders, W.E., et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 174 (2014), 1340–1348.
14. Thorvaldsen, T., Benson, L., Dahlstrom, U., Edner, M., Lund, L.H., Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail 18 (2016), 503–511.
15. Lund, L.H., Svennblad, B., Dahlstrom, U., Stahlberg, M., Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure. Eur J Heart Fail 20 (2018), 769–777.
16. Schocken, D.D., Arrieta, M.I., Leaverton, P.E., Ross, E.A., Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 20 (1992), 301–306.
17. Ghali, J.K., Pina, I.L., Gottlieb, S.S., Deedwania, P.C., Wikstrand, J.C., Group, M.-H.S., Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 105 (2002), 1585–1591.
18. Simon, T., Mary-Krause, M., Funck-Brentano, C., Jaillon, P., Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 103 (2001), 375–380.
19. Martinez-Selles, M., Doughty, R.N., Poppe, K., et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail 14 (2012), 473–479.
20. O'Meara, E., Clayton, T., McEntegart, M.B., et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 115 (2007), 3111–3120.
21. Bourassa, M.G., Gurne, O., Bangdiwala, S.I., et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 22 (1993), 14A–19A.
22. Tamargo, J., Rosano, G., Walther, T., et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovascular pharmacotherapy 3 (2017), 163–182.
23. Ghali, J.K., Krause-Steinrauf, H.J., Adams, K.F., et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 42 (2003), 2128–2134.
24. Tsuji, K., Sakata, Y., Nochioka, K., et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur J Heart Fail 19 (2017), 1258–1269.
25. Piro, M., Della Bona, R., Abbate, A., Biasucci, L.M., Crea, F., Sex-related differences in myocardial remodeling. J Am Coll Cardiol 55 (2010), 1057–1065.
26. Lund, L.H., Carrero, J.J., Farahmand, B., et al. Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study. Eur J Heart Fail 19 (2017), 1107–1116.